182 related articles for article (PubMed ID: 38274823)
61. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract][Full Text] [Related]
62. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
63. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
[TBL] [Abstract][Full Text] [Related]
64. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
65. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.
Insinga RP; Feliciano JL; Qiao N; Vandormael K; Zhang Y
J Med Econ; 2021; 24(1):792-805. PubMed ID: 34098842
[TBL] [Abstract][Full Text] [Related]
67. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina.
Wurcel V; Chirovsky D; Borse R; Altuna JI; Carabajal F; Gandhi J
Adv Ther; 2021 May; 38(5):2613-2630. PubMed ID: 33855690
[TBL] [Abstract][Full Text] [Related]
68. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
[TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
70. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
[TBL] [Abstract][Full Text] [Related]
71. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
[TBL] [Abstract][Full Text] [Related]
73. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
74. Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis.
Liu K; Zhu Y; Zhou Y; Zhu H
Adv Ther; 2023 Apr; 40(4):1838-1849. PubMed ID: 36870042
[TBL] [Abstract][Full Text] [Related]
75. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lang Y; Dong D; Wu B
Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
[TBL] [Abstract][Full Text] [Related]
76. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
[TBL] [Abstract][Full Text] [Related]
77. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan.
Mo X; Moriwaki K; Morimoto K; Shimozuma K
Clin Drug Investig; 2022 Jul; 42(7):599-609. PubMed ID: 35675029
[TBL] [Abstract][Full Text] [Related]
78. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ;
N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429
[TBL] [Abstract][Full Text] [Related]
79. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
[TBL] [Abstract][Full Text] [Related]
80. Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India-A Model-Based Economic Analysis.
Gupta N; Nehra P; Chauhan AS; Mehra N; Singh A; Krishnamurthy MN; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Kataki AC; Dixit J; Gupta S; Kumar L; Prinja S
JCO Glob Oncol; 2022 Mar; 8():e2100355. PubMed ID: 35286136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]